Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
remynd logo — company profile

remynd

Founded 2002 Belgium Belgium 30 employees Series B Total: $24.00M Biotechnology, Manufacturing

General Information

Company Name remynd
Founded Year 2002
Location Belgium Belgium +1
Employees 30
Industries Biotechnology, Manufacturing
Funding Stage Series B
Social

Get notified when remynd moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About remynd

remynd is a clinical-stage biotechnology company focused on innovating oral therapeutics for neurodegenerative diseases like Alzheimer’s and Huntington’s disease. Founded in 2002 and headquartered in Belgium, the company strives to tackle disease mechanisms, aiming to enhance neuronal function and curb disease progression.

Through an unwavering commitment to innovation and measurable patient impact, remynd is advancing its therapies from initial discovery to clinical development. The company successfully executed a €12.00 million Series B investment on 21 January 2021, backed by distinguished investors such as BNP Paribas Fortis, FPIM, PMV, Korys, and KU Leuven.

Positioned within the Biotechnology and Manufacturing industries, remynd seeks further investor support to fuel its growth trajectory and achieve pivotal strides in neurodegenerative disease treatment.

Services & Products

Development of oral treatments for neurodegenerative diseases
Contract Research Organization services
Proof-of-concept studies in mouse models

Target Customers

Pharmaceutical companies Biopharmaceutical researchers Drug developers Healthcare stakeholders

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 5
Investor Investor Investor Investor
•••• •••• 		21 Jan 2021
Series B •••••• 5
Investor Investor Investor
•••• •••• 		18 Dec 2018

remynd Alternatives & Competitors

View All Alternatives
remynd vs
Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc. United States

Dedicated to developing life-changing medicines for patients and families living with challenging di...

Post Ipo Equity
19 employees
Biotechnology, Health Care
Compare remynd vs Cyclo Therapeutics, Inc.
remynd vs
Cholesgen
Cholesgen

Pioneering the future of medicine through groundbreaking drug development and advanced biopharmaceut...

Series A
Biotechnology, Pharmaceutical
Compare remynd vs Cholesgen
remynd vs
Aramis Biosciences
Aramis Biosciences United States

Disease-Modifying Therapy for Ocular Surface Disease

Seed
3 employees
Biotechnology, Health Care
Compare remynd vs Aramis Biosciences
View all alternatives

FAQ About remynd

Remynd is a clinical-stage biotechnology company dedicated to developing first-in-class oral therapeutics for neurodegenerative diseases, including Alzheimer’s disease and Huntington’s disease. By targeting the underlying disease mechanisms, reMYND aims to restore neuronal function and slow disease...
remynd was founded in 2002.
remynd is headquartered in Belgium.
remynd operates in the following industries: Biotechnology, Manufacturing.
remynd has approximately 30 employees.
remynd has completed 2 funding rounds, raising a total of $24.00M. The latest funding stage is Series B.
remynd offers: Development of oral treatments for neurodegenerative diseases, Contract Research Organization services, Proof-of-concept studies in mouse models.
Top alternatives and competitors to remynd include Cyclo Therapeutics, Inc., Cholesgen, Aramis Biosciences, Allyx Therapeutics, Avolynt, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
remynd and Cyclo Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors remynd and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy